Strand Therapeutics is a clinical-stage biotechnology company that employs synthetic biology to genetically engineer mRNA for advanced immunotherapies. Founded by a team of biological engineers from MIT, Strand is pioneering the development of smart therapies using a novel mRNA programming language, enabling therapeutic proteins to be encoded onto innovative mRNA frameworks. The company is advancing its lead program, STX-001, which is currently in a Phase 1 clinical trial for solid tumors, alongside a diverse portfolio of preclinical programs. With its headquarters in Boston's Fenway district, Strand focuses on creating therapies that can respond to specific cellular environments through programmed logic circuits. The company emphasizes collaboration, innovation, and a commitment to improving patient outcomes through cutting-edge science and technology.